ROTEM®- The standard of Patient careIt was shown that, besides the better patient care, effective cost savings are possible by following a ROTEM® guided therapy.
The economic as well as the clinical effectiveness of ROTEM®-diagnostic was demonstrated in clinical studies and health technology assessments. This resulted in recommendations such as the ESA guideline, the ASA guideline, the NICE recommendation, the PPH guidance of the SSC ISTH and the European Trauma Guideline.
Proven cost saving potential
The use of ROTEM® as a diagnostic tool in perioperative bleeding management is implemented in numerous guidelines like:
- Liver transplant
The cost saving potential of ROTEM®-guided therapy has repeatedly been proven. It significantly reduces unnecessary blood product use and clinical complications. The reduced complication rate may have an additional cost saving aspect by reducing intensive care unit and hospital stay time!
The cost of blood products are a significant part of hospital expenses and are increasing, with annual rises of 10% or more. Prices driven by increasing numbers of surgical procedures are likely to increase further when demand cannot be matched by the steadily declining donor pool in our aging population. Moreover, directly related costs such as storing, testing and administering blood products are constantly underestimated in hospital budgets, yet these costs can be a significant part of the total cost to the hospital.
For references see brochure
Improved patient outcome
Substantial blood savings of up to 50% can be realized through individualized bleeding management and with comprehensive diagnostic results. In particular, thromboelastometry with ROTEM® has been proven to decrease transfusion volumes and shorten durations of hospital stay in elective procedures, such as liver transplantation and cardiac surgery. Similar cost-savings are being investigated in other application fields such as trauma care (polytrauma, brain injury, etc.), obstetrics (e.g. post-partum haemorrhage) or orthopaedics.